Valuation
- Market cap
- 1,031,409,000
- Revenue TTM
- $0
- Net income TTM
- $-118,840,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.21
Trading
- Volume
- 1,741,300
- Avg volume
- 2,151,706
- Day's range
- $4.91 – $5.14
- Shares out
- 205,460,000
- Stochastic %K
- 82%
- Beta
- 0.20
- Analysts
- Strong Sell
- Price target
- $11.05
Company profile
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Yardley, Pennsylvania.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- (512) 614-1848
- Website
- https://www.savarapharma.com
- Address
- The Tannery Building, Suite 200 19 West College Avenue, Yardley, United States
Latest news
No headlines yet.
